NP031112, a Thiadiazolidinone Compound, Prevents Inflammation and Neurodegeneration under Excitotoxic Conditions: Potential Therapeutic Role in Brain Disorders
Rosario Luna‐Medina(Consejo Superior de Investigaciones Científicas), Ana Pérez‐Castillo(Instituto de Investigaciones Biomédicas Sols-Morreale), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Marta Cortés‐Canteli(Spanish National Centre for Cardiovascular Research), Susana Sanchez-Galiano(Consejo Superior de Investigaciones Científicas), José Á. Morales-García(Universitat de Vic - Universitat Central de Catalunya), Ángel Santos(Universidad Complutense de Madrid)
Cited by 114
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293